CommercialCoverageLow impact
RNA-Targeted Therapies (Amvuttra ® and Onpattro ® )
UnitedHealthcare·Neurology, Cardiology, Internal Medicine·Medical Benefit Drug Policy
Effective date
Jun 1, 2026
We identified it
Jun 2, 2026
Summary
UnitedHealthcare updated their Medical Benefit Drug Policy for RNA-targeted therapies Amvuttra and Onpattro effective June 1, 2026. This policy change affects coverage criteria and billing requirements for these specialized hereditary transthyretin amyloidosis medications.
Action Required
By June 1, 2026: Billing team should review the updated RNA-targeted therapy policy for Amvuttra and Onpattro to understand any new coverage criteria or prior authorization requirements. Update billing procedures for these specialty medications if your practice treats hereditary transthyretin amyloidosis patients.